Table 1.
Summary of selected studies assessing salivary hepcidin concentration in various clinical contexts.
| First author, year | Study population | Number of participants | Age, years (Mean ± SD) | Sex of participants (M/F) | Hepcidin assay | Salivary hepcidin concentration [ng/mL] (Mean ± SD or Median [IQR]) | Key findings |
|---|---|---|---|---|---|---|---|
| Arnold, J., 2010 (5) | Healthy individuals | 17 | 35 ± 9.9 | 8/9 | RIA | 3.39 ± 2.83 | Hepcidin is detectable in saliva |
| Cicek, D., 2014 (6) | Behçet’s disease (BD) | 25 | 34.48 ± 6.9 | 13/12 | ELISA | 657.58 ± 358.25 | Increased hepcidin concentration in RAS patients |
| Recurrent aphthous stomatitis (RAS) | 30 | 31.56 ± 11.5 | 15/15 | 443.10 ± 249.68 | |||
| Healthy individuals | 25 | 31.52 ± 6.2 | 13/12 | 714.10 ± 280.58 | |||
| Guo, L. N., 2018 (7) | Chronic periodontitis (CP) | 22 | 58.09 ± 9.97 | 16/6 | ELISA | 1.64 [0.93, 3.19] | No significant differences between study groups |
| Type 2 diabetes mellitus (T2DM) | 22 | 56.45 ± 11.80 | 15/7 | 1.54 [0.99, 3.80] | |||
| CP+T2DM | 22 | 62.82 ± 10.72 | 17/5 | 1.79 [0.93, 5.14] | |||
| Healthy individuals | 22 | 52.45 ± 10.01 | 14/8 | 1.12 [0.89, 1.73] |
BD, Behçet’s disease; CP, Chronic periodontitis; ELISA, Enzyme-linked immunosorbent assay; F, Female; IQR, Interquartile range; M, Male; RAS, Recurrent aphthous stomatitis; RIA, Radioimmunoassay; SD, Standard deviation; T2DM, Type 2 diabetes mellitus.